ERBB2 and breast cancer: Another phase I study investigated an anti-HER2 DC-based vaccination on 13 patients with HER2 IHC3+ DCIS BC in the neoadjuvant setting showing specific activation of T cells, accumulation of T and B lymphocytes in the breast, and induction of tumor-lytic antibodies [182].